AIM ImmunoTech (AIM) investor relations material

Executive summary

• Focus shifted to developing Ampligen for late-stage pancreatic cancer, leveraging positive clinical data, orphan drug designations in the US and EU, and completion of enrollment and dosing in the Phase 2 DURIPANC trial, advancing toward a pivotal Phase 3 study.

• Multiple equity transactions in Q2 2026 raised $10.4 million, improving liquidity and resolving NYSE American compliance issues.

• Ampligen is also being explored for antiviral and infectious disease applications, including government-funded programs like Ebola, but further R&D is paused pending pancreatic cancer trial results.

• Strengthened financial position and operational execution support continued clinical development.

Financial highlights

• Net loss for Q2 2026 was $3.8 million, or $(0.43) per share, up from $2.8 million, or $(3.68) per share, in Q2 2025, mainly due to equity transaction costs.

• Cash and cash equivalents rose to $9.9 million as of June 30, 2026, from $3.0 million at year-end 2025, a $6.9 million increase over six months.

• Research and development expenses for Q2 2026 declined 49.8% year-over-year to $589,000, reflecting a shift in clinical focus and completion of a Phase II study.

• General and administrative expenses nearly doubled year-over-year to $2.9 million due to legal and accounting fees tied to equity offerings.

Outlook and guidance

• Topline results from the DURIPANC Phase 2 pancreatic cancer trial are expected in Q1 2027, with Overall Survival data anticipated in Q3 2027.

• Plans to initiate a pivotal Phase 3 trial for Ampligen in pancreatic cancer after DURIPANC results and protocol finalization, leveraging observed median Overall Survival improvement.

• Short-term working capital needs estimated at $7.2–$10.8 million annually, with additional funding likely required for future studies and commercialization.

• Pursuing non-dilutive government funding for infectious disease programs while maintaining oncology as the primary focus.